No CrossRef data available.
Article contents
Itraconazole: A New Triazole Antifungal Agent
Published online by Cambridge University Press: 02 January 2015
Abstract
The azole antifungal agents represent a major advance in the management of superficial and systemic fungal infections. Itraconazole appears to have a broad spectrum of in vitro activity and is the first azole antifungal agent to have activity against Aspergillus species. Itraconazole acts primarily by impairing the synthesis of ergosterol, resulting in a defective fungal cell membrane with altered permeability and function. It is effective for a wide variety of mycotic infections and some fungal meningeal infections. Most adverse effects have been relatively minor and do not lead to discontinuation of therapy.
- Type
- Clinical Pharmacology of Antibiotics
- Information
- Copyright
- Copyright © The Society for Healthcare Epidemiology of America 1994
References
1.Cleary, JD, Taylor, JW, Chapman, SW. Itraconazole in antifungal therapy. Ann Pharmacother 1992;26:502–509.Google Scholar
3.Yoshida, Y, Aoyama, Y. Interaction of azole antifungal agents with cytochrome F450 purified from Saccharomyces cerevisiae microsomes. Biochem Phamnacol 1987;36:229–235.Google Scholar
4.Borgers, M. Mechanism of action of antifungal drugs, with special reference to the imidazole derivative. Rev Infect Dis 1980;2:520–534.Google Scholar
5.Sud, IJ, Feingold, DS. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol 1981;76:438–441.Google Scholar
6.Sud, IJ, Feingold, DS. Heterogenicity of action mechanisms among antimycotic imidazoles. Antimicrob Agents Chemother 1981;20:71–74.Google Scholar
7.Odds, FC, Cockayne, A, Hayward, J, et al.Effects of imidazole and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. J Gen Microbial 1985;131:2581–2589.Google Scholar
8.Borgers, M, Van de Ven, M. Degenerative changes in fungi after itraconazole treatment. Rev Infect Dis 1987;9(suppl 1):S33–S42.Google Scholar
9.Del Palacio-Hemanz, A, Frias-Iniesta, J, Gonzalez-Valle, O, et al.Itraconazole therapy in pityriasis versicolor. Br J Derm 1986;115:217–225.Google Scholar
10.Graybill, JR. Future directions of antifungal chemotherapy. Clin Infect Dis 1992:14:(suppl 1):S170–S181.Google Scholar
11.Sheehan, DJ, Espinel-Ingroff, A, Moore, LS, Webb, CD. Antifungal susceptibility testing of yeasts: a brief overview. Clin Infect Dis 1993;17(suppl 2):S494–S500.Google Scholar
12.Van Cutsem, J, Van Gerven, F, Janssen, PAJ. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987:9(suppl 1):S15–S32.Google Scholar
13.Espinel-Ingroff, A, Shaddmy, S, Gebhart, RJ. In vitro studies with R51,211 (itraconazole). Antimicrob Agents Chemother 1984;26:5–9.Google Scholar
14.Graybill, JR, Stevens, DA, Galgiani, JN, Dismukes, WE, Cloud, GA. Itraconazole treatment of coccidioidomycosis. Am J Med 1990;89:282–290.Google Scholar
15.DuPont, B, Drouhet, E. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. Rev Infect Dis 1987;9(supp1 1):S71–S76.Google Scholar
16.Denning, DW, Tucker, RM, Hanson, LH, Stevens, DATreatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791–800.Google Scholar
17.Heykants, J, Van Peer, A, Lavrijsen, K, Meuldermans, W, Woestenborghs, R, Cauwenbergh, G. Pharmacokinetics of oral antifungals and their clinical implications. Br J Clin Pract 1990;44(suppl 9):50–56.Google Scholar
18.Barone, JA, Koh, JG, Bierman, RH, et al., Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993;37:778–784.Google Scholar
19.Van Perr, A, Woestenborghs, R, Heykants, J, Gasparini, R, Cauwenbergh, G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989;36:423–426.Google Scholar
20.Wishart, JM. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J Am Acad Dermatol 1987;17:220–223.Google Scholar
21.Smith, D, Van de Velde, V, Woestenborghs, R, Gazzard, BG. The nharmacokinetics of oral itraconazole in AIDS patients. J Pharm Phamtacol 1992;44:618–619.Google Scholar
22.Lake-Bakaar, G, Tom, W, Lake-Bakaar, D, et al.Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;109:471–473.Google Scholar
23.Tricot, G, Joosten, E, Boogaerts, MA, Vande Pitte, J, Cauwenbergh, G. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987;9(suppl 1):S94–S99.Google Scholar
24.Hardin, TC, Graybill, JR, Fetchick, R, Woestenborghs, R, Rinaldi, MG, Kuhn, JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988;32:1310–1313.Google Scholar
25.Larosa, E, Cauwenbergh, G, Cilli, P, Woestenborghs, R, Heykants, J. Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. Eur J Obstet Gynecol Reprod Biol 1986;23:85–89.Google Scholar
26.Cauwenbergh, G, Degreef, H, Heykants, J, Woestenborghs, R, Van Rooy, P, Haeverans, K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988;18:263–268.Google Scholar
27.Willemsen, M, De Doncker, P, Willems, J. Posttreatment itraconazole levels in the nail. J Am Acad Dermatol 1992;26:731–735.Google Scholar
28.Van Cauteren, H, Heykants, J, De Coster, R, Cauwenbergh, G. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis 1987;9(suppl 1):S43–S46.Google Scholar
29.Heykants, J, Van Peer, A, Van de Velde, P, et al.The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32(suppl 1):67–87.Google Scholar
30.Boelaert, J, Schurgers, M, Matthys, E, et al.Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 1988;32:1595–1597.Google Scholar
31.Degreef, H, Marien, K, De Veylder, H, Duprez, K, Borghys, A, Verhoeve, L. Itraconazole in the treatment of dermatophytoses: a comparison of two daily dosages. Rev Infect Dis 1987;9(suppl 1):S104–S108.Google Scholar
32.Saul, A, Bonifaz, A, Arias, I. Itraconazole in the treatment of superficial mycoses: an open trial of 40 cases. Rev Infect Dis 1987;9(suppl 1):S100–S103.Google Scholar
33.Nuijten, STM, Schurgers, JL. Itraconazole in the treatment of tinea corporis: a pilot study. Rev Infect Dis 1987;9(suppl 1):s119–s120.Google Scholar
34.Panconesi, E, Difonzo, E. Treatment of dermatophytoses and pityriasis versicolor with itraconazole. Rev Infect Dis 1987;9(suppl 1):S109–S113.Google Scholar
35.Akantara, R, Garibay, JM. Itraconazole therapy in dermatomycosis and vaginal canhidiasis: efficacy and adverse effects profile in a large multicenter study. Adv Ther 1988;5:326–333.Google Scholar
36.Bourloid, A, Lachapelle, JM, Aussems, J, et al.Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruis. Int J Dermatol 1989;28:410–412.Google Scholar
37.Panagiotidou, D, Kousidou, T, Chaidemenos, G. A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study. J Intern Med Res 1992;20:392–400.Google Scholar
38.Lachapelle, JM, De Doncker, P, Tennstedt, D, Cauwenbergh, G, Janssen, PA. Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of all completed double-blind studies with respect to the pharmacokinetic profile. Dematology 1992;184:45–50.Google Scholar
39.Roseeuw, D, Willemsen, M, Kint, RT, Peremans, W, Mertens, RLJ, Van Cutsem, J. Itraconazole in the treatment of superficial mycoses-a double-blind study vs. placebo. Clin Exp Dermatol 1990;15:101–104.Google Scholar
40.Faergemann, J. Treatment of pityriasis versicolor with itraconazole: a double-blind placebo controlled study. Mycoses 1988;31:377–379.Google Scholar
41.Galimberti, RL, Villalba, I, Galarza, S, Raimondi, A, Flores, V. Itraconazole in pityriasis versicolor: ultrastructural changes in Malassezia furfur produced during treatment. Rev Infect Dis 1987;9(suppl 1):S134–S138.Google Scholar
42.Morales-Doria, M. Pityriasis versicolor: efficacy of two five-day regimens of itraconazole. Rev Infect Dis 1987;9(suppl 1):S131–S133.Google Scholar
43.Delescluse, J. Itraconazole in tinea versicolor: a review. J Am Acad Dermatol 1990;23:551–554.Google Scholar
44.Del Palacio-Hemanz, A, Delnado Vicente, S. Menendez Ramos, F, Rodriguez-Noriega Belaugtegui, A. Randdmized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev Infect Dis 1987;9(suppl 1): S121–S127.Google Scholar
45.Grant, SM. Clissold SE Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310–344.Google Scholar
46.Cauwenbergh, G, DeDoncker, P, Stoops, K, De Dier, DM, Goyvaerts, H, Schuermans, V. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev Infect Dis 1987;9(suppl 1):S146–S152.Google Scholar
47.Silva-Cruz, A, Andrade, L, Sobral, L, Francisca, A. Itraconazole versus placebo in the management of vaginal candidiasis. Int J Gynaecol Obstet 1991;36:229–232.Google Scholar
48.Sanz Sanz, F, Del Palacio-Hernanz, A. Randomized comparative trial of three regimens of itraconazole for treatment of vaginal mycoses. Rev Infect Dis 1987;9(suppl 1):S139–S142.Google Scholar
49.Wesel, S. Itracdnazole: a single-day oral treatment for acute vulvovaginal candidosis. Br J Clin Pract Symp Suppl 1990;71:77–80.Google Scholar
50.Stein, GE, Mummaw, N. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob Agents Chemother 1993;37:89–92.Google Scholar
51.Tobin, JM, Loo, P, Granger, SE. Treatment of vaginal candidosis: a comparative study of the efficacy and acceptability of itraconazole and clotrimazole. Genitourin Med 1992;68:36–38.Google Scholar
52.Merkus, TM, Van Heusden, AM. Chronic vulvovaainal candidosis: the role of oral treatment. Br J Clin Practr Symp Suppl 1990;71:81–84.Google Scholar
53.Fong, IW. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourin Med 1992;68:374–377.Google Scholar
54.Blatchford, NR. Treatment of oral candidosis with itraconazole: a review. J Am Acad Dermatol 1990;23:565–567.Google Scholar
55.Smith, DE, Midgley, J, Allan, M, Connolly, GM, Gazzard, BG. Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS 1991;5:1367–1371.Google Scholar
56.Hay, RJ, Clayton, YM, Moore, MK, Midgely, G. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988;119:359–366.Google Scholar
57.Piepponen, T, Blomqvist, K, Brandt, H, et al.Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother 1992;29:195–205.Google Scholar
58.Arenas, R, Fernandez, G, Dominguez, L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 1991;30:586–589.Google Scholar
59.Viviani, MA, Tortorano, AM, Langer, M, et al.Experience with itraconazole in ctyptococcosis and aspergillosis. J Infect 1989;18:151–165.Google Scholar
60.Viviani, MA, Tortorano, AM, Pagano, A, et al.European experience with itraconazole in systemic mycoses. J Am Acad Dermatol 1990;23:587–593.Google Scholar
61.Denning, DW, Tucker, RM, Hanson, LH, Hamilton, JR, Stevens, DA. Itraconazole therapy for cryptococcal meningitis and cryntococcosis. Arch Intern Med 1989;149:2301–2308.Google Scholar
62.Denning, DW, Tucker, RM, Hanson, LH, Stevens, DA. Itraconazole in opportunistic mycoses: cryptococcosis and aspergillosis. J Am Acad Dermatol 1990;23:602–607.Google Scholar
63.de Gans, J, Portegies, P, Tiessens, G, et al.Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185–190.Google Scholar
64.Powderly, WG, Saag, MS, Cloud, GA, et al.A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793–798.Google Scholar
65.DuPont, B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990;23:607–614.Google Scholar
66.Phillips, P, Fetchick, R, Weisman, I, Foshee, S, Graybill, JRTolerance to and efficacy of itraconazole in treatment of systemic mycoses: preliminary results. Rev Infect Dis 1987;9(suppl 1):S87–S93.Google Scholar
67.Thomas, PA, Abraham, DJ, Kalavathy, CM, Rajasekaran, J. Oral itraconazole therapy for mycotic keratitis. Mycoses 1988;31:271–279.Google Scholar
68.Negroni, R, Palmieri, O, Koren, F, Tiraboschi, IN, Galimberti, RL. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Rev Infect Dis 1987;9(suppl 1):S47–s50.Google Scholar
69.Negroni, R, Robles, AM, Arechavala, A, Taborda, A. Itraconazole in human histonlasmosis. Mycoses 1989;32:123–130.Google Scholar
70.Dismukes, WE, Bradsher, RW JrCloud, GC, et al.Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992;93:489–497.Google Scholar
71.Dismukes, WE, Cloud, G, Bowles, C, et al.Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med 1985;103:861–872.Google Scholar
72.Sharkey-Mathis, PK, Velez, J, Fetchick, R, Graybill, JR. Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole. J Acquir Immune Defic Syndr 1993;6:809–819.Google Scholar
73.Negroni, R, Taborda, A, Robles, AM, Arechavla, A. Itraconazole in the treatment of histoplasmosis associated with AIDS. Mycoses 1992;35:281–287.Google Scholar
74.Wheat, J, Hafner, R, Wulfsohn, M, et al.Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:610–616.Google Scholar
75.Wheat, J, Connolly-Stringfield, PA, Baker, RL, et al.Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine 1990;69:361–374.Google Scholar
76.Borelli, D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Rev Infect Dis 1987;9(suppl 1):S57–S63.Google Scholar
77.Restrepo, A, Gomez, I, Robledo, J, Patino, MM, Cano, LE. Itraconazole in the treatment of paracoccidioidomycosis: a preliminary report. Rev Infect Dis 1987;9(suppl 1):S51–S56.Google Scholar
78.Naranio, MS, Trujillo, M, Munera, MI, Restrepo, P, Gomez, I, Restrepo, A. Treatment of paracoccidioidomycosis with itraconazole. J Med Vet Mycol 1990;28:67–76.Google Scholar
79.Tucker, RM, Denning, DW, Arathoon, EG, Rinaldi, MG, Stevens, DA. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol 1990;23:593–601.Google Scholar
80.Diaz, M, Puente, R, de Hoyos, LA, Cruz, S. Itraconazole in the treatment of coccidioidomycosis. Chest 1991;100:682–684.Google Scholar
81.Tucker, RM, Denning, DW, Dupont, B, Stevens, DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990;112:108–112.Google Scholar
82.Lavalle, P, Suchil, P, De Ovando, F, Revnoso, S. Itraconazole for deep mycoses: preliminary experience in Mexico. Rev Infect Dis 1987;9(suppl 1):S64–S70.Google Scholar
83.Restrepo, A, Robledo, J, Gomez, I, Tabares, AM, Gutierrez, R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986;122:413–417.Google Scholar
84.Sharkey-Mathis, PK, Kauffman, CA, Graybill, JR, et al.Treatment of sporotrichosis with itraconazole. Am J Med 1993;95:279–285.Google Scholar
85.Winn, RE, Anderson, J, Piper, J, Aronson, NE, Pluss, J. Systemic sporotrichosis treated with itraconazole. Clin Infect Dis 1993;17:210–217.Google Scholar
86.al-Fouzan, AS, al-Saleh, QA, Najem, NM, Rostom, AI. Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole. Int J Dermatol 1991;30:519–521.Google Scholar
87.Albanese, G, Giorgetti, P, Santagostino, L, Crippa, D, Sala, G. Cutaneous leishmaniasis. Treatment with itraconazole. Arch Dermatol 1989;125:1540–1542.Google Scholar
88.Dogra, J, Aneja, N, Lal, BB, Mishra, SN. Cutaneous leishmaniasis in India. Clinical exnerience with itraconazole (R51 211 Janssen). Int J Demzatol 1990;29:661–662.Google Scholar
89.Sharkey, PA, Graybill, JR, Rinaldi, MG, et al.Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol 1990;23:577–586.Google Scholar
90.Ganer, A, Arathoon, E, Stevens, DA. Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev Infect Dis 1987;9(suppl 1): S77–S86.Google Scholar
91.Thunnissen, PL, Sizoo, W, Hendriks, WD. Safety and efficacy of itraconazole in preventing fungal infections in neutropenic patients. Neth I Med 1991;39:84–91.Google Scholar
92.Boogaerts, MA, Verhoef, GE, Zachee, P, Demuynck, H, Verbist, L, De Beule, K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32(suppl 1):103–108.Google Scholar
93.Persat, F, Marzullo, C, Guyotat, D, Rochet, MJ, Piens, MA. Plasma itraconazole concentrations in neutropenic patients after reneated high-dose treatment. Eur J Cancer 1992;28:838–841.Google Scholar
94.Van't Wout, JW, Novakova, I, Verhagen, CA, et al.The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomized comparative study with amphotericin B. J Infect 1991;22:45–52.Google Scholar
95.Tucker, RM, Haq, Y, Denning, DW, Stevens, DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26:561–566.Google Scholar
96.Lavrijsen, APM, Balmus, KJ, Nugteren-Huying, , Roldaan, AC, Van't Wout, JW, Stricker, BHC. Henatic iniurv associated with itraconazole~ Lancet 340;1992:251–252.Google Scholar
97.Sharkey, PK, Rinaldi, MG, Dunn, JF, Hardin, TC, Fetchik, RJ, Graybill, JR. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35:707–713.Google Scholar
98.Phillips, P, Graybill, JR, Fetchick, R, Dunn, JEAdrenal response to corticotropin therapy with itraconazole. Antimicrob Agents Chemother 1987;31:647–649.Google Scholar
99.Crane, JK, Hue-Teh, S. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am/ Med 1993;95:445–446.Google Scholar
100.Honig, PK, Wortham, DC, Zamani, K, et al.Terfenadine-ketoconazole interaction, pharmacokinetic and electrocardiomanhic consequences. JAMA 1993;269:1513–1518.Google Scholar
101.Mathews, DR, McNutt, B, Okerholm, R, Flicker, M, McBride, G. Torsade de pointes occurring in association with terfenadine use. JAMA 1991;266:2375–2376.Google Scholar
102.Monahan, BP, Ferguson, CL, Killeavy, ES, LLoyd, BK, Troy, J, Cantilena, LR. Torsade de pointes occurring in association with terfenadine use. JAMA 1990;264:2788–2789.Google Scholar
103.Tucker, RM, Denning, DW, Hanson, LH, et al.Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165–174.Google Scholar
105.Moreno, F, Hardin, TC, Rinaldi, MG, Graybill, JR. Itraconazole-didanosine excioient interaction. JAMA 1993;269:1508.Google Scholar
106.Kwan, JTC, Foxall, PJD, Davidson, DCG, Bending, MR, Eisinger, AJ. Interaction of cyclosporin and itraconazole. Lancet 1987;2:282.Google Scholar
107.Novakova, I, Donnelly, P, De Witte, T, et al.Itraconazole and cyclosporin nephrotoxicity. Lancet 1987;2:920–921.Google Scholar
108.Shaw, MA, Gumbleton, M, Nicholls, PJ. Interaction of cyclosporin and itraconazole. Lancet 1987;2:267.Google Scholar
109.Kramer, MR, Marshall, SE, Denning, DW, et al.Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990;113:327–329.Google Scholar
110.Kauffman, CA, Bagnasco, FA. Digoxin toxicity associated with itraconazole therapy. Clin Infect Dis 1992;15:886–887.Google Scholar
112.Sachs, MK, Blanchard, LM, Green, PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993;16:400–403.Google Scholar
- 13
- Cited by